Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotreatment with FLT3 inhibitors and inhibitors of JAK or PIM kinases blocks GM-CSF and IL-3 rescue of cell survival in vitro and in vivo.
|
30944098 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-3 and GM-CSF modulate functions of splenic macrophages in ENU induced leukemia.
|
28039843 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest a possible tumor-suppressor role of GM-CSF in RUNX1-ETO leukemia.
|
22223820 |
2012 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results establish the safety and immunogenicity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic HSCT, and raise the possibility that this combinatorial immunotherapy might potentiate graft-versus-leukemia in patients.
|
19717467 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
|
16547503 |
2006 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have previously shown efficient insertion of GM-CSF and CD80 genes into primary human leukemia cells with the use of second and third generation self-inactivating (SIN) lentiviral vectors (Blood 96 (2000), 1317; Leukemia 16 (2002), 1645).
|
12850480 |
2004 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1).
|
14562045 |
2003 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In some cases, endogenous GM-CSF expression by transduced AML cells induced phenotypic changes consistent with the maturation of leukemia blasts into antigen-presenting cells.
|
12200676 |
2002 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data strongly suggest that leukemia cell production of GMCSF rarely occurs in vivo.
|
10880262 |
2000 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The average amount of GM-CSF secretion by the leukemia cell lines transduced with the pHR-GM-CSF monocistronic vector was 2182.9 pg/10(6) cells per 24 hours.
|
10942373 |
2000 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that transgenic SCID mice expressing human IL-3 and GM-CSF provide a useful system for the study of human leukemia.
|
9714520 |
1998 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensitivity of CFU-L to DT388-GMCSF was seen regardless of the clinical responsiveness of the patient's leukemia to standard chemotherapy agents.
|
9657759 |
1998 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings identify the molecular basis for the autocrine TNFalpha activation of the GM-CSF gene in JMML and suggest potential novel and specific approaches for the treatment of this aggressive childhood leukemia.
|
9185524 |
1997 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, murine A20 leukemia cells transduced with a DISC-HSV vector encoding granulocyte-macrophage colony-stimulating factor were able to stimulate a potent antitumor response in mice, even against pre-existing leukemia.
|
8978284 |
1997 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To measure an effect on cells with in vivo leukemia initiating potential DT-GM-CSF exposed AML cells were transplanted into immunodeficient mice.
|
9345060 |
1997 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings prompted us to establish five ALL cell lines of diverse phenotypes to examine the expression of GM-CSF and GM-CSF receptor genes in human leukemia, and to determine the role of GM-CSF in autocrine and paracrine growth control of ALL cells.
|
8499641 |
1993 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conditioned media (CM) from a human lung adenocarcinoma cell line expressing interleukins 1 and 6 (IL-1, IL-6), granulocyte (G), macrophage (M), and GM colony-stimulating factors (G, M, GM-CSF) and transforming growth factor beta (TGF beta) were used to stimulate growth of bone marrow (BM) cells from 18 persons with leukemia, myelodysplastic syndrome, or lymphoma.
|
2331674 |
1990 |